Matinas BioPharma (MTNB) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $53.8M

Matinas BioPharma (NYSE: MTNB) reported Q3 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02).

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• CalPrivate Bank names Andra Frazier as chief credit officer